Earnings call transcript: eXoZymes Q1 2025 unveils innovation and market strategy
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates a mixed sentiment. While there are opportunities in the medical field and potential partnerships, there are also significant risks, such as regulatory issues and supply chain challenges. The Q&A reveals optimism about NCT's market potential, but management's lack of specific guidance and clarity on future products tempers expectations. Additionally, the financials show increased expenses without a change in cash reserves, suggesting limited growth. These factors, combined with the competitive pressures and economic uncertainties, suggest a neutral impact on stock price.
Key Financial Performance
Cash and Cash Equivalents $8,510,000, no year-over-year change mentioned.
Total Operating Expenses $1,950,000, an increase of 9% or $42,000 compared to Q1 2024, primarily driven by R&D investments and professional expansion.
Net Loss $1,860,000, no year-over-year change mentioned.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
NCT Launch: Exoscience has launched NCT, a compound with potential benefits for fatty liver metabolism, gut barrier function, and mitochondrial health, marking a significant step in their commercialization efforts.
Synbio Beta Conference: Exoscience attended the Synbio Beta 2025 conference, where they announced the spin-out of NCTx and engaged in over 60 meetings to explore partnerships and enhance brand recognition.
Cash Position: As of March, Exoscience reported cash and cash equivalents of $8,510,000, ensuring liquidity for ongoing operations into 2026.
Operating Expenses: Total operating expenses for Q1 2025 were $1,950,000, reflecting a 9% increase due to R&D investments and expansion of the leadership team.
Rebranding Success: The recent rebranding campaign has significantly increased Exoscience's visibility, evidenced by a sixfold increase in LinkedIn followers and substantial media coverage.
Focus on Nutraceuticals and Pharmaceuticals: Exoscience is strategically focusing on nutraceuticals for faster market entry while also exploring pharmaceutical potentials through the development of analogs.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Issues: There is uncertainty regarding future grants, which may impact funding opportunities for the company.
Supply Chain Challenges: The company is concerned about the potential difficulties in securing grants and funding, which could affect their operational capabilities.
Economic Factors: The current economic climate presents uncertainty, which could impact the company's growth and investment opportunities.
Competitive Pressures: The company faces competition in the synthetic biology space, particularly regarding the commercialization of NCT and its analogs.
Operational Efficiency: The company emphasizes the need for capital efficiency and prioritization of essential expenditures to navigate uncertain times.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
NCTX Launch: The launch of NCTX marks the first commercial value and inflection point for Exoscience, focusing on the development of N transcaphamyltyramine for nutrition and pharmaceutical applications.
Rebranding Campaign: The rebranding campaign has significantly increased brand recognition and visibility in the synthetic biology space.
Partnership Development: The company aims to create connections and explore partnership possibilities for Enzyme Services and NCTX, with over 60 unique meetings held at the Synbio Beta conference.
Focus on Capital Efficiency: Exoscience emphasizes capital efficiency and prioritization of essential expenditures to maximize shareholder value.
Spinout Strategy: The decision to spin out NCTX is aimed at accelerating market entry and demonstrating the power of Exoscience's technology.
Cash Position: As of March, cash and cash equivalents stood at $8,510,000, providing sufficient liquidity to support operations into 2026.
Operating Expenses: Total operating expenses for Q1 2025 were $1,950,000, primarily driven by R&D investments.
Net Loss: The net loss for the quarter was $1,860,000, reflecting disciplined spending and targeted investments.
Future Revenue Expectations: While specific revenue projections were not disclosed, the company anticipates significant opportunities in addressing the unmet medical need of fatty liver disease.
Funding Opportunities: Exoscience continues to explore non-dilutive funding opportunities, strategic partnerships, and potential government grants to strengthen its financial position.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Cash and Cash Equivalents: As of March, our cash and cash equivalents stood at $8,510,000.
Total Operating Expenses: Our total operating expenses for the quarter were $1,950,000.
Net Loss: The net loss for the quarter was $1,860,000.
Shareholder Value Focus: We remain disciplined in our spending approach and ensure capital is allocated efficiently to maximize shareholder value.
Non-Dilutive Funding: We continue to explore non-dilutive funding opportunities, strategic partnerships and potential government grants to further strengthen our financial position.
NCT Spinout: The first fully owned subsidiary is focused here short term because we can much faster bring these guys to market and also learn from the development while we are building these things at scale.
Ownership Structure: If you’re an investor in Exoscience already, then you are indirectly already an owner of NCTX.
Future Partnerships: We will soon be issuing a call for partnerships, reaching out broadly to whoever would be interested in participating in building NCTX.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why was NCT chosen as Exoscience’s first commercial compound?
A:NCT was chosen because our technology is a good fit for that specific compound, and there is a significant market opportunity. Other players have invested heavily in NCT, but we can produce solutions much faster and more efficiently.
Q:Can you explain to your investors why you are taking the approach that you are to spin out NTT as opposed to doing other types of monetization?
A:The spin out allows us to show the market how quickly we can progress with NCT, demonstrating the power of our platform while also creating the NCT opportunity.
Q:Tell us more about the new natural product and what is in the pipeline for health and nutrition.
A:Natural products are a good fit for us because they have established benefits, and we can leverage existing genetic codes to develop biosolutions. Future products will likely be health and nutrition-oriented.
Q:Will Exoscience seek patent protection for the NCT variants?
A:Yes, we have already filed a patent application for the analogs of NCT.
Q:On the Exercise website, it states that NCT X is the only company that can make NCT and its analogs. Could you elaborate on that?
A:While other companies have explored NCT, they face challenges in production. Our technology allows us to create analogs that provide competitive advantages.
Q:How will launching NTT help with future compound launches or spinouts? What are the main lessons Exoscience hopes to learn from this first adventure?
A:We aim to learn how to balance the focus on nutraceuticals and pharmaceuticals, ensuring scalability and efficiency in future projects.
Q:Can you estimate how large the NCT opportunity could be over time?
A:I cannot provide specific numbers yet, but addressing fatty liver disease represents a significant market opportunity.
Q:What’s the impact of getting the cover story in Gen Biotechnology?
A:It establishes us as a key opinion leader in biomanufacturing and highlights the importance of our work in the industry.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numerical estimates for the potential size of the NCT opportunity, stating that they would provide more precise guidance in the future. Additionally, there was a lack of clarity on the exact details of future products in the pipeline.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO
Communications Exoscience
Gales VP
NCT
NCTX
VP Communications
advantage
analog
biomanufacturing
cell
company
compound
conference
conversation
course
day
development
exoscience
fit
focus
future
investor
liver
lot
market
nature
news
number
opportunity
partner
people
perspective
point
potential
product
question
side
space
spin
story
technology
today
value
video
way
week
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
